On Janaushadhi Diwas this year (i.e., March 7th, 2022), Prime Minister Shri Narendra Modi stated that the poor and the middle-class benefited from the 'Jan Aushadhi Kendras' that were set up to provide generic drugs at affordable prices. He said that the poor and the middle class saved around Rs.13,000 crore through these stores during the COVID-19 pandemic. In the wake of COVID 19 crisis, the 'Bureau of Pharma PSUs of India'...

-PTI/ Livemint.com * Being Health Minister of the country, how justified is it to release such falsely fabricated unscientific product, the IMA statement said * The IMA statement further said: Can you clarify the time frame, time line for the so-called clinical trial of this said anti-corona product The Indian Medical Association (IMA) on Monday said that it shocked over Patanjali Ayurveda's "blatant lie of WHO certification" for Coronil tablet, which the company...

-The Hindu They advise against Covaxin, say there is no proof of efficacy. Several experts have raised concern over the “hasty approval” granted to the COVID-19 vaccines despite the lack of adequate efficacy data. The Central Drugs Standard Control Organisation on Sunday accorded approval for restricted emergency use of the Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India (SII), and the indigenously developed vaccine Covaxin of Bharat Biotech. “I’m completely unaware...

-Livemint.com India has adopted a cautious approach in granting approval to covid-19 vaccines as fast tracking, safety and efficacy remain primary concern NEW DELHI: Safety and efficacy are the primary concerns of the government while granting emergency use authorization (EUA) to any covid-19 vaccine in the country. The government's cautious approach before approving a vaccine is apparent. The meeting of the subject expert committee of Central Drugs Standards Control Organisation on Wednesday asked...

-The Hindu CDSCO sends letter to manufacturers Alerted by the Union Health Ministry’s pharmaceutical watchdog, the National Co-ordination Centre of the Pharmacovigilance Programme of India (PvPI), on adverse reactions that were being reported from some commonly-used antibiotics, the Central Drugs Standard Control Organisation (CDSCO) has now asked manufacturers to ensure that this information be made available to the general public. CDSCO has written to drug manufacturers, to mention in leaflets inserted into drug...